Royal Philips Electronics (NYSE: PHG, AEX: PHI) and GlyGenix Therapeutics, Inc. (Woodbridge, Connecticut, USA) announced a joint research agreement to explore the feasibility of using ultrasound technologies for gene therapy. In particular, the collaboration will research the treatment of Glycogen Storage Disease Type 1a (GSD-1a) in pre-clinical studies. The collaboration unites Philips’ expertise in medical imaging technologies for diagnosis and minimally-invasive medical procedures with